Halozyme Therapeutics Inc.
HALO
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.32B
Close$
$93.78
22.8% downside
Current Fair Value
22.8% downsideOvervalued by 22.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.32 Billion |
|---|---|
| Enterprise Value | $15.31 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.64 |
| Beta | 0.88 |
| Outstanding Shares | 117,274,000 |
Return
| Return on Equity | 288.13% |
|---|---|
| Return on Assets | 16.05% |
| Return on Invested Capital | 42.54% |
Valuation & Multiples
| P/E Ratio | 31.37 |
|---|---|
| PEG | 80.01 |
| Price to Sales | 8.68 |
| Price to Book Ratio | 121.51 |
| Enterprise Value to Revenue | 9.2 |
| Enterprise Value to EBIT | 16.12 |
| Enterprise Value to Net Income | 37 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 14.95 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$1.79
Average shareholder expectationRevenue Estimate
$402.28 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$2.30
Average shareholder expectationRevenue Estimate
$490.85 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 61.67% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.14%▼ 103.31% |
|---|---|
| Total Invested | $277.43M▼ 97.15% |
| Investors Holding | 31▼ 658.00% |
ESG Score
No data
About Halozyme Therapeutics Inc.
423 employees
CEO: Helen Torley Halozyme Therapeutics, Inc., a biopharmaceutical technology company, was established in 1998 and is based in San Diego, California. The company's operations span globally, covering markets in the United States, Switzerland, Ireland, Belg...